ALSO READScientists reverse Alzheimer's disease in mouse model Anxiety: An early indicator of Alzheimer's disease? Lack of sleep boosts levels of Alzheimer's proteins: study Scientists develop world's first blood test to detect Alzheimer's Researchers discover 'switch' which can turn off inflammation
The research, published in the Journal of Experimental Medicine, paves the way for drugs that may successfully treat Alzheimer's disease in humans.
Drugs that inhibit BACE1 are therefore being developed as potential Alzheimer's disease treatments but, because BACE1 controls many important processes by cleaving proteins other than APP, these drugs could have serious side effects.
Mice completely lacking BACE1 suffer severe neurodevelopmental defects.
To investigate whether inhibiting BACE1 in adults might be less harmful, researchers generated mice that gradually lose this enzyme as they grow older.
These mice developed normally and appeared to remain perfectly healthy over time.
The resulting offspring also formed plaques at this age, even though their BACE1 levels were approximately 50 per cent lower than normal.
However, the plaques began to disappear as the mice continued to age and lose BACE1 activity, until, at 10 months old, the mice had no plaques in their brains at all.
"To our knowledge, this is the first observation of such a dramatic reversal of amyloid deposition in any study of Alzheimer's disease mouse models," said Riqiang Yan, from Cleveland Clinic Lerner Research Institute.
Decreasing BACE1 activity also resulted in lower beta-amyloid peptide levels and reversed other hallmarks of Alzheimer's disease, such as the activation of microglial cells and the formation of abnormal neuronal processes.
Loss of BACE1 also improved the learning and memory of mice with Alzheimer's disease.
However, when the researchers made electrophysiological recordings of neurons from these animals, they found that depletion of BACE1 only partially restored synaptic function, suggesting that BACE1 may be required for optimal synaptic activity and cognition.
"Our study provides genetic evidence that preformed amyloid deposition can be completely reversed after sequential and increased deletion of BACE1 in the adult," said Yan.
"Our data show that BACE1 inhibitors have the potential to treat Alzheimer's disease patients without unwanted toxicity," he said.
"Future studies should develop strategies to minimize the synaptic impairments arising from significant inhibition of BACE1 to achieve maximal and optimal benefits for Alzheimer's patients," he added.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)